Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung bath chemo during surgery aims to wipe out hidden sarcoma cells

NCT ID NCT02811523

Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a technique called in vivo lung perfusion (IVLP) that delivers chemotherapy directly into the lung during surgery to remove sarcoma tumors that have spread to the lungs. The goal is to kill any tiny cancer cells left behind that could cause the cancer to come back, while reducing side effects on the rest of the body. About 17 people with sarcoma in both lungs will take part. One lung will get the IVLP treatment and the other will receive standard care, so doctors can compare safety and effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 17 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2016

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Soft Tissue or Osteogenic Sarcoma * Presence of bilateral pulmonary metastases * 3 or more lung lesions in total * Age less than 65 years * ECOG 0-2 * Absence of extra-pulmonary disease * Contralateral disease amenable to surgery or radiation * All lung lesions in the lung to be treated with IVLP can be resected with wedge or segmental resections (non-IVLP treated lung will be treated with radiation or surgery 4-12 weeks prior to IVLP) Exclusion Criteria: * Patient has previously received more than 450 mg of doxorubicin * Left Ventricular Ejection Fraction \<50% * History of significant pulmonary disease or pneumonitis * Pregnant or lactating females * Age 65 years or older, or less than 18 years * Inability to understand the informed consent process * Hypersenstivity to doxorubicin * Current participation in another therapeutic clinical trial * Previous lung metastatectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone cancer bone sarcoma metastatic neoplasm osteosarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone sarcoma Pulmonary metastases Soft tissue sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.